Literature DB >> 14717332

Synthesis and characterization of a Gd-DOTA-D-permeation peptide for magnetic resonance relaxation enhancement of intracellular targets.

Andrew M Prantner1, Vijay Sharma, Joel R Garbow, David Piwnica-Worms.   

Abstract

Many MR contrast agents have been developed and proven effective for extracellular nontargeted applications, but exploitation of intracellular MR contrast agents has been elusive due to the permeability barrier of the plasma membrane. Peptide transduction domains can circumvent this permeability barrier and deliver cargo molecules to the cell interior. Based upon enhanced cellular uptake of permeation peptides with D-amino acid residues, an all-D Tat basic domain peptide was conjugated to DOTA and chelated to gadolinium. Gd-DOTA-D-Tat peptide in serum at room temperature showed a relaxivity of 7.94 +/- 0.11 mM(-1) sec(-1) at 4.7 T. The peptide complex displayed no significant binding to serum proteins, was efficiently internalized by human Jurkat leukemia cells resulting in intracellular T1 relaxation enhancement, and in preliminary T1-weighted MRI experiments, significantly enhanced liver, kidney, and mesenteric signals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14717332     DOI: 10.1162/153535003322750673

Source DB:  PubMed          Journal:  Mol Imaging        ISSN: 1535-3508            Impact factor:   4.488


  8 in total

1.  Synthesis and characterization of gadolinium-Peptidomimetic complex as an αvβ3 integrin targeted MR contrast agent.

Authors:  Young-Seung Kim; Yang Zhou; Henry Bryant; Diane E Milenic; Kwamena E Baidoo; Bobbi K Lewis; Joseph A Frank; Martin W Brechbiel
Journal:  Bioorg Med Chem Lett       Date:  2015-04-04       Impact factor: 2.823

2.  Cell-penetrating peptides: Possible transduction mechanisms and therapeutic applications.

Authors:  Zhengrong Guo; Huanyan Peng; Jiwen Kang; Dianxing Sun
Journal:  Biomed Rep       Date:  2016-03-23

Review 3.  A review of responsive MRI contrast agents: 2005-2014.

Authors:  Dina V Hingorani; Adam S Bernstein; Mark D Pagel
Journal:  Contrast Media Mol Imaging       Date:  2014-10-29       Impact factor: 3.161

4.  In vivo imaging with a cell-permeable porphyrin-based MRI contrast agent.

Authors:  Taekwan Lee; Xiao-an Zhang; Shanta Dhar; Henryk Faas; Stephen J Lippard; Alan Jasanoff
Journal:  Chem Biol       Date:  2010-06-25

5.  Peptidyl molecular imaging contrast agents using a new solid-phase peptide synthesis approach.

Authors:  Byunghee Yoo; Mark D Pagel
Journal:  Bioconjug Chem       Date:  2007-03-02       Impact factor: 4.774

6.  Structural characterization of a dimeric complex between the short cytoplasmic domain of CEACAM1 and the pseudo tetramer of S100A10-Annexin A2 using NMR and molecular dynamics.

Authors:  Weidong Hu; Supriyo Bhattacharya; Teresa Hong; Patty Wong; Lin Li; Nagarajan Vaidehi; Markus Kalkum; John E Shively
Journal:  Biochim Biophys Acta Biomembr       Date:  2020-08-21       Impact factor: 3.747

7.  Blood-brain barrier permeable gold nanoparticles: an efficient delivery platform for enhanced malignant glioma therapy and imaging.

Authors:  Yu Cheng; Qing Dai; Ramin A Morshed; Xiaobing Fan; Michelle L Wegscheid; Derek A Wainwright; Yu Han; Lingjiao Zhang; Brenda Auffinger; Alex L Tobias; Esther Rincón; Bart Thaci; Atique U Ahmed; Peter C Warnke; Chuan He; Maciej S Lesniak
Journal:  Small       Date:  2014-08-08       Impact factor: 13.281

8.  Spatiotemporal quantification of local drug delivery using MRI.

Authors:  Morgan B Giers; Alex C McLaren; Jonathan D Plasencia; David Frakes; Ryan McLemore; Michael R Caplan
Journal:  Comput Math Methods Med       Date:  2013-04-24       Impact factor: 2.238

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.